Insider Transactions in Q2 2021 at Flexion Therapeutics Inc (FLXN)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2021
|
Alan Milinazzo Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+14.08%
|
-
|
|
Jun 24
2021
|
Patrick J Mahaffy Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+10.15%
|
-
|
|
Jun 24
2021
|
Heath Lukatch Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+33.33%
|
-
|
|
Jun 24
2021
|
Mark Stejbach Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+26.27%
|
-
|
|
Jun 24
2021
|
Samuel D Colella Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+28.67%
|
-
|
|
Jun 24
2021
|
Scott A Canute Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+33.33%
|
-
|
|
Jun 24
2021
|
C Ann Merrifield Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+19.15%
|
-
|
|
Jun 24
2021
|
Elizabeth Kwo Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+50.0%
|
-
|
|
Jun 21
2021
|
Michael D. Clayman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,700
+0.49%
|
$11,900
$7.78 P/Share
|
|
Jun 21
2021
|
Kerry Wentworth Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
539
+0.37%
|
$3,773
$7.78 P/Share
|
|
Jun 21
2021
|
Adam Muzikant Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,081
+1.93%
|
$14,567
$7.78 P/Share
|
|
Jun 01
2021
|
Frederick W Driscoll Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,000
+47.72%
|
-
|
|
May 10
2021
|
David Arkowitz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,229
-1.0%
|
$15,603
$7.23 P/Share
|